873857-62-6 | Fidaxomicin

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$45.00	$32.00

Description

• Catalog Number: AB47675
• Chemical Name: Fidaxomicin
• CAS Number: 873857-62-6
• Molecular Formula: C52H74Cl2O18
• Molecular Weight: 1058.0392
• MDL Number: MFCD27976367
• SMILES: CO[C@@H]1[C@H](OC/C/2=C\C=C\C[C@H](O)/C(=C/[C@H](CC)[C@H](/C(=C/C(=C/C[C@H](OC2=O)[C@H](O)C)/C)/C)O[C@@H]2OC(C)(C)[C@H]([C@@H]([C@@H]2O)O)OC(=O)C(C)C)/C)O[C@@H]([C@H]([C@@H]1O)OC(=O)c1c(O)c(Cl)c(c(c1CC)Cl)O)C

Computed Properties

• Complexity: 1970
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 14
• Defined Bond Stereocenter Count: 5
• Heavy Atom Count: 72
• Hydrogen Bond Acceptor Count: 18
• Hydrogen Bond Donor Count: 7
• Rotatable Bond Count: 15
• XLogP3: 6.4

Literature

• Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801

• Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801

• Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801

• Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801

• Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801

• Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801

• Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801

• Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801

• Fidaxomicin inhibits spore production in Clostridium difficile.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801

• Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801

• New drugs 2012, part 2.

  Nursing 20120701

• Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120601

• Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.

  Future microbiology 20120601

• Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

  The Lancet. Infectious diseases 20120401

• Progress with a difficult infection.

  The Lancet. Infectious diseases 20120401

• Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120215

• Annual drug update: 2011 in review.

  The Nurse practitioner 20120212

• Clostridium difficile infection in older adults: a review and update on its management.

  The American journal of geriatric pharmacotherapy 20120201

• Fidaxomicin for the treatment of Clostridium difficile infections.

  The Annals of pharmacotherapy 20120201

• Fidaxomicin, a new treatment for Clostridium difficile infections.

  Drugs of today (Barcelona, Spain : 1998) 20120201

• Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.

  Clinical therapeutics 20120101

• Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price.

  Clinical drug investigation 20120101

• Fidaxomicin: in Clostridium difficile infection.

  Drugs 20111224

• Comparative effectiveness of Clostridium difficile treatments: a systematic review.

  Annals of internal medicine 20111220

• Clostridium difficile infection: clinical spectrum and approach to management.

  Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology 20111201

• Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110901

• Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.

  Pharmacotherapy 20110901

• Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

  Journal of medical microbiology 20110801

• Characterization of a sugar-O-methyltransferase TiaS5 affords new Tiacumicin analogues with improved antibacterial properties and reveals substrate promiscuity.

  Chembiochem : a European journal of chemical biology 20110725

• Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection.

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20110701

• Fidaxomicin: first-in-class macrocyclic antibiotic.

  Expert review of anti-infective therapy 20110701

• Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.

  Managed care (Langhorne, Pa.) 20110701

• Fidaxomicin for Clostridium difficile Infection.

  The New England journal of medicine 20110512

• Fidaxomicin for Clostridium difficile infection.

  The New England journal of medicine 20110512

• Fidaxomicin versus vancomycin for Clostridium difficile infection.

  The New England journal of medicine 20110203

• The search for effective treatment of Clostridium difficile infection.

  The New England journal of medicine 20110203

• Characterization of tiacumicin B biosynthetic gene cluster affording diversified tiacumicin analogues and revealing a tailoring dihalogenase.

  Journal of the American Chemical Society 20110202

• 'Game changer' antibiotic and others in works for superbug.

  Nature medicine 20110101

• Rivaroxaban, ticagrelor, and fidaxomicin.

  Journal of the American Pharmacists Association : JAPhA 20110101

• Management of Clostridium difficile infection: thinking inside and outside the box.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101201

• A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.

  Microbiology (Reading, England) 20101101

• New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile.

  Expert opinion on therapeutic patents 20101001

• Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.

  Expert opinion on pharmacotherapy 20100601

• Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

  Expert review of anti-infective therapy 20100501

• Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.

  Future microbiology 20100401

• Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model.

  Journal of ethnopharmacology 20090706

• Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.

  The Journal of antimicrobial chemotherapy 20081001